Declared Dividend • Jun 20
Dividend of CN¥0.49 announced Shareholders will receive a dividend of CN¥0.49. Ex-date: 26th June 2026 Payment date: 26th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 20% per year over the past 8 years. However, payments have been volatile during that time. EPS is expected to grow by 52% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 24
DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026 DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 15, 2026, at 10:00 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China Announcement • Apr 23
DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million. DaShenLin Pharmaceutical Group Co., Ltd. (SHSE:603233) signed a equity transfer agreement to acquire Sipai Zhihe Technology (Guangzhou) Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million on April 22, 2026. The consideration is CNY 51.73 million (all PRC stamp duties in relation to this transaction shall be borne by the Seller), representing the valuation of the target and target subsidiaries and subject to adjustment. The Consideration shall be paid by the Purchaser to the Seller in five instalments and subject to the special payment arrangement: The first instalment of CNY 4.674 million shall be paid to the Seller within 15 business days after the date of the Equity Transfer Agreement; second instalment of CNY 16.2362 million shall be paid to the Seller within 15 business days after completion of the changes to effect the Disposal, third instalment of CNY 17.0828 million shall be paid to the Seller within 15 business days after completion of operational handover matters and certain qualifications confirmed by the Purchaser, fourth instalment of CNY 2.46 million shall be paid to the Seller within 15 business days after delivery of operating systems and data to the Purchaser; and the fifth instalment of CNY 7.337 million shall be paid to the Seller within 15 business days after the earlier of (a) the first anniversary of the Closing Date; or (b) the second anniversary of the date of the equity transfer agreement. Pursuant to the Equity Transfer Agreement, an amount representing no more than 50% of the third instalment attributable to specific pharmacies may be withheld by the Purchaser and an additional CNY 3.94 million may be payable depending on the status of the lease agreement entered as prescribed by the equity transfer agreement.
If any target subsidiaries are unable to operate normally following completion, the consideration shall be reduced by an amount equal to the attributed valuation of such target subsidiaries. In the event that the net assets of the target company at the closing date exceed the target net asset value of CNY 2.59 million, the consideration should be adjusted upwards to reflect the excess net asset, provided that net asset value at the closing date shall not exceed CNY 30 million and in any event, the total consideration (after any upward adjustment) shall not exceed CNY 79.14 million.
As of March 31, 2026, Sipai Zhihe Technology (Guangzhou) Co., Ltd. reported total common equity of CNY 15.08 million.
The completion of this transaction is contingent upon several key financial, operational, and structural conditions. Financially, the target company must maintain consolidated net assets of at least CNY 2.59 million and have accurate, compliant financial records. Operationally, all its subsidiaries must hold the necessary licenses and qualifications. Within 45 days after the date of the equity transfer agreement, the Reorganization should be completed and all of the target subsidiaries should become wholly-owned subsidiary of Sipai Zhihe Technology (Guangzhou) Co., Ltd.
The net proceeds from the transaction will be applied for corporate purposes and as general working capital of the group.
Ignite Capital Limited acted as financial advisor for Sipai Health. Announcement • Mar 30
DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 Announcement • Dec 26
DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 24, 2026 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 24, 2026 Announcement • Sep 30
DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Apr 26
DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025 DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2025, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China Announcement • Mar 28
DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 27
DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 Valuation Update With 7 Day Price Move • Nov 07
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥16.98, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 14x in the Consumer Retailing industry in China. Total loss to shareholders of 33% over the past three years. Reported Earnings • Nov 05
Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.22 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.17 (down from CN¥0.22 in 3Q 2023). Revenue: CN¥6.39b (up 11% from 3Q 2023). Net income: CN¥200.5m (down 22% from 3Q 2023). Profit margin: 3.1% (down from 4.5% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Sep 30
DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥14.81, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Consumer Retailing industry in China. Total loss to shareholders of 47% over the past three years. Reported Earnings • Sep 01
Second quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.38 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.23 (down from CN¥0.38 in 2Q 2023). Revenue: CN¥6.59b (up 9.1% from 2Q 2023). Net income: CN¥259.1m (down 38% from 2Q 2023). Profit margin: 3.9% (down from 7.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Jun 28
DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2024 results on Aug 31, 2024 Declared Dividend • Jun 19
Dividend of CN¥0.31 announced Shareholders will receive a dividend of CN¥0.31. Ex-date: 21st June 2024 Payment date: 21st June 2024 Dividend yield will be 1.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (33% earnings payout ratio) and cash flows (17% cash payout ratio). The dividend has increased by an average of 5.7% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 74% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • Jun 14
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. GM & Director Guoqiang Ke was the last director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Apr 30
DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024 DaShenLin Pharmaceutical Group Co., Ltd., Annual General Meeting, May 20, 2024, at 10:30 China Standard Time. Location: The Company's Meeting Room, Guangzhou, Guangdong China Reported Earnings • Apr 29
First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.43 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.35 (down from CN¥0.43 in 1Q 2023). Revenue: CN¥6.75b (up 14% from 1Q 2023). Net income: CN¥398.5m (down 20% from 1Q 2023). Profit margin: 5.9% (down from 8.4% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Announcement • Mar 30
DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2022). Revenue: CN¥5.73b (up 12% from 3Q 2022). Net income: CN¥256.9m (up 23% from 3Q 2022). Profit margin: 4.5% (up from 4.1% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 31
Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.28 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.38 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥6.05b (up 20% from 2Q 2022). Net income: CN¥420.7m (up 28% from 2Q 2022). Profit margin: 7.0% (up from 6.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Announcement • Jun 28
DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 DaShenLin Pharmaceutical Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Apr 28
Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021) Full year 2022 results: EPS: CN¥1.09 (up from CN¥0.83 in FY 2021). Revenue: CN¥21.2b (up 27% from FY 2021). Net income: CN¥1.04b (up 31% from FY 2021). Profit margin: 4.9% (up from 4.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 3% per year. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥43.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 49% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥62.56 per share. Valuation Update With 7 Day Price Move • Nov 18
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥45.38, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 55% over the past three years. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 29
Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.22 (up from CN¥0.18 in 3Q 2021). Revenue: CN¥5.10b (up 19% from 3Q 2021). Net income: CN¥209.1m (up 21% from 3Q 2021). Profit margin: 4.1% (up from 4.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year and the company’s share price has also increased by 3% per year. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥34.59, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 22x in the Consumer Retailing industry in China. Total returns to shareholders of 4.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥63.02 per share. Reported Earnings • Aug 31
Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.34 (up from CN¥0.32 in 2Q 2021). Revenue: CN¥5.04b (up 26% from 2Q 2021). Net income: CN¥330.0m (up 8.2% from 2Q 2021). Profit margin: 6.5% (down from 7.6% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 17% growth forecast for the Consumer Retailing industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • May 28
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥33.25, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Consumer Retailing industry in China. Total returns to shareholders of 6.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.90 per share. Reported Earnings • Apr 29
Full year 2021 earnings released: EPS: CN¥1.00 (vs CN¥1.35 in FY 2020) Full year 2021 results: EPS: CN¥1.00 (down from CN¥1.35 in FY 2020). Revenue: CN¥16.8b (up 15% from FY 2020). Net income: CN¥791.2m (down 26% from FY 2020). Profit margin: 4.7% (down from 7.3% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 28%, compared to a 17% growth forecast for the retail industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Jan 01
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥42.11, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 26x in the Consumer Retailing industry in China. Total returns to shareholders of 110% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥23.30 per share. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥4.30b (up 21% from 3Q 2020). Net income: CN¥172.7m (down 37% from 3Q 2020). Profit margin: 4.0% (down from 7.7% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year whereas the company’s share price has increased by 25% per year. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥4.00b (up 12% from 2Q 2020). Net income: CN¥305.1m (down 3.0% from 2Q 2020). Profit margin: 7.6% (down from 8.8% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥47.25, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 25x in the Consumer Retailing industry in China. Total returns to shareholders of 102% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥90.11 per share. Reported Earnings • Apr 20
Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥14.6b (up 31% from FY 2019). Net income: CN¥1.06b (up 51% from FY 2019). Profit margin: 7.3% (up from 6.3% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Mar 10
New 90-day low: CN¥75.58 The company is down 9.0% from its price of CN¥82.79 on 10 December 2020. The Chinese market is down 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.96 per share. Is New 90 Day High Low • Jan 25
New 90-day high: CN¥105 The company is up 22% from its price of CN¥86.12 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥64.40 per share. Valuation Update With 7 Day Price Move • Jan 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥89.60, the stock is trading at a trailing P/E ratio of 57.3x, up from the previous P/E ratio of 49.6x. This compares to an average P/E of 35x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 198%. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥93.33, the stock is trading at a trailing P/E ratio of 59.7x, up from the previous P/E ratio of 50x. This compares to an average P/E of 34x in the Consumer Retailing industry in China. Total returns to shareholders over the past three years are 208%. Is New 90 Day High Low • Jan 04
New 90-day low: CN¥76.99 The company is down 7.0% from its price of CN¥82.46 on 30 September 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share. Is New 90 Day High Low • Dec 19
New 90-day low: CN¥78.69 The company is down 2.0% from its price of CN¥80.30 on 21 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Consumer Retailing industry, which is down 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥66.94 per share. Is New 90 Day High Low • Nov 14
New 90-day high: CN¥99.20 The company is up 41% from its price of CN¥70.39 on 14 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥57.01 per share. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.01b, up 50% from the prior year. Total revenue was CN¥13.6b over the last 12 months, up 28% from the prior year. Is New 90 Day High Low • Oct 29
New 90-day high: CN¥92.06 The company is up 20% from its price of CN¥76.50 on 31 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Consumer Retailing industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥49.33 per share.